SYSTEMATIC REVIEW article
Front. Med.
Sec. Ophthalmology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1542440
This article is part of the Research TopicBeyond Boundaries: A Multidisciplinary Journey into Vernal KeratoconjunctivitisView all articles
The impact of tacrolimus therapy on the outcomes of Vernal Keratoconjunctivitis; A Systematic Review and Meta-analysis
Provisionally accepted
- College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background; Various preparations of tacrolimus have been implemented for patients with vernal keratoconjunctivitis (VKC). However, there is a lack of evidence regarding the safety and effectiveness of different dosages and forms of tacrolimus for patients with VKC.The present systematic review and meta-analysis evaluated the safety and effectiveness of various dosages and forms of tacrolimus for patients with VKC.The literature review was performed through twelve databases on 15 June 2024. All clinical studies comparing the outcomes of different dosages and tacrolimus preparations for VKC were included. Subgroup analysis was performed based on the dosages and formulations of tacrolimus.The present meta-analysis included 17 articles, encompassing 832 patients with VKC. Of them, 421 patients received tacrolimus, while 411 patients were in the control group. Of the treated patients with tacrolimus, 66 were treated with tacrolimus ophthalmic suspension 0.1%, and 62 were treated with tacrolimus 0.1% ointment. Furthermore, 293 patients were treated with tacrolimus 0.03% ointment. There was a statistically significant (P=0.02) difference between tacrolimus and the control group regarding the mean score for objective signs with SMD of -0.70 (95%CI;-1.28,-0.13). A statistically significant difference (P<0.001) was observed between the tacrolimus ophthalmic suspension 0.1% and the control group with an SMD of -1.09 (95%CI;-1.59,-0.59). There was a significantly lower total subjective symptom score among patients treated with tacrolimus with an SMD of -0.86 (95%CI;-1.44,0.28) and a probability value of 0.004. A statistically significant lower risk of treatment-related adverse events was revealed among patients treated with tacrolimus 0.03% ointment (P=0.0002) with an RR of 0.16.Tacrolimus is an effective and safe therapeutic intervention for patients with VKC.It remarkably reduced the total score for objective signs and total subjective symptom score of VKC, with a relatively lower risk of treatment-related adverse events. The improvement of clinical manifestations was significantly associated with tacrolimus ophthalmic suspension 0.1%, while tacrolimus 0.03% ointment was associated with the lowest risk of treatment-related adverse events.
Keywords: Tacrolimus, Vernal keratoconjunctivitis, ointment, Suspension, VKC
Received: 09 Dec 2024; Accepted: 14 Jul 2025.
Copyright: © 2025 AlHuthail. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Reem AlHuthail, College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.